Ultragenyx drug apazunersen misses main goal in late-stage trial
Ultragenyx Pharmaceutical said its experimental apazunersen for Angelman syndrome did not meet the main goal in a late-stage trial, sending shares down 40% in after-hours trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.